FH and renal carcinoma: In xenograft models, an 8-week treatment with vandetanib substantially increased tumor-free survival to 13 months, indicating that ABL1 inhibition could be a viable clinical strategy for managing aggressive FH-deficient renal cancers and other glycolysis- and oxidative stress-driven tumors.